Frontier Science Scotland’s Post

Humanized Mouse and Rat Model Market Worth $349 Million Download a PDF Brochure: https://lnkd.in/dphHE_PP Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, Crown Bioscience, Champions Oncology, Inc., Hera BioLabs, genOway, Inotiv, Vitalstar Biotechnology (China), ingenious targeting laboratory, TRANS GENIC (Japan), Harbour Antibodies, Oncodesign Services, Pharmatest Services, Ozgene, TransCure bioServices, Cyagen, Aragen Life Sciences, GemPharmatech, and Biocytogen Other Companies that are Operating in this Market Globally: Neuroscience Group IntraNerve Neuroscience Myriad Neuroscience Pacific Neuroscience Institute (PNI) National Neuroscience Institute NEUROSCIENCE & SPINE ASSOCIATES Riverhills Neuroscience OPENMINDS Centre for Psychiatry, Counselling and Neuroscience    WVU Rockefeller Neuroscience Institute Korle-Bu Neuroscience Foundation Lifespan Stanford Health Care Baptist Health Indiana University Health King Faisal Specialist Hospital and Research Center      Semel Institute for Neuroscience and Human Behavior   Atlantic Health System Allegheny Health Network Memorial Healthcare System CHOC Children's Hoag Health System St. Luke's University Health Network    #HumanizedMouse #HumanizedRat #AnimalModels #HealthTech #Biotechnology #MedicalResearch #PreclinicalStudies #PharmaceuticalResearch #HealthcareInnovation #LabResearch #BiomedicalResearch #TranslationalMedicine #DiseaseModels #ScientificResearch #MedicalInnovation #ClinicalResearch #ResearchModels #HealthDiagnostics #PharmaResearch #MarketResearch

🧠 The future of #neurotherapeutics is now! Attend this #BIO2024 panel to hear from top leaders in the field as they discuss groundbreaking tools and strategies for treating brain disorders.

Are you attending #BIO2024? Don’t miss our panel on the most pressing unmet need in medicine: brain disorders. Hear from Basking CEO Rich Shea and other #neurology and #biotech leaders about how innovative technologies to uncover the function and dysfunction of the brain at the molecular and cellular level are transforming #neurotherapeutics. 🧠 Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision Neurotherapeutics 🗓️ Tuesday June 4 ⌚ 11 am - 12 pm PT 📍 26A 🔹Alaa Halawa, MBA, Executive Director and Head of Healthcare, US Ventures, Mubadala Capital 🔹Carol Suh, MBA, Co-founder & Chief Operating Officer, Neumora 🔹Joanne Taylor, PhD, Senior Vice President, Research, Gain Therapeutics 🔹Rich Shea, MBA, CEO, Basking Biosciences 🔹Craig Thompson, CEO, Cerevance https://lnkd.in/eUz8vPrg #pharma #drugdiscovery #drugdelivery #innovation #stroke #drugdevelopment #clinicalresearch #clinicaltrials #neurology

I am excited to announce a research collaboration between Axxam, a leader in Screening technologies and High Content Imaging, and Tessara Therapeutics, renowned for their expertise in creating #humanBrainOrganoids. Together, we develop complex cellular models of co-cultured human neurons and glial cells in microplate formats for image-based analysis using High Content Screening microscopy (Opera Phenix by Revvity). Our collaboration exemplifies the power of combining cutting-edge imaging technology with advanced organoid models to push the boundaries of neuroscience research. 🎥 Check out our latest movie, showcasing a 3D reconstruction of a brain organoid in a miniaturized format. The first seconds provide a maximum projection overview, followed by a detailed representation of the volumetric structure of part of the organoid (left) and a magnified region with higher resolution (right). The green color highlights the β-III tubulin staining for neurites, while the red color indicates the signal from glial cells. This cell culture system can be utilized to test the effects of drugs on human neuronal disease models, providing critical insights into neurogenesis and neuroplasticity within a organ-like context. The use of organoid systems will allow to pharmacologically interrogate yet unprecedented biology. Stay tuned for more updates on our research and the future of drug discovery! #Axxam #TessaraTherapeutics #HighContentImaging #BrainOrganoids #Neuroscience #Innovation #DrugDiscovery #RealBrain

Impact Factor: 4.8 | Volume 22, Issues 14, 2024 🔹 Indexed in: Scopus, SCI Expanded, MEDLINE/PubMed 🔹 Ranking: 69th in Neurosciences | 40th in Pharmacology & Pharmacy Aims & Scope: Current Neuropharmacology publishes comprehensive and mini-reviews on molecular, cellular, and systems/behavioral neuropharmacology and neuroscience. We also consider novel position papers, research articles, and clinical trials. Guest-edited issues span all areas of neuropharmacology. 🔬 Stay updated with the latest advancements in neuropharmacology and neuroscience. Explore innovative research and expert reviews in our latest issue! 🔗https://bit.ly/3X34vh4 Learn more and submit your work today!

The #optogenetics market is expected to continue growing as researchers explore its potential across various fields, including #neuroscience, #biotechnology, and #medicine. Technological advancements, such as the development of more precise optogenetic tools and delivery methods, are driving this growth. Additionally, increased funding for neuroscience research and the rising prevalence of #neurological disorders contribute to market expansion. Coherent Corp., Noldus Information Technology, Thorlabs, Bruker, Laserglow Technologies, Regenex, GenSight Biologics, The Jackson Laboratory, Applied Materials, Circuit, Elliot Scientific Ltd., Shanghai Electric Group Co., Ltd, Optics Center, Addgene, Scientifica , Judges Scientific Plc, Prizmatix Ltd., Danaher Corporation, Thorlabs #marketanalysis #marketgrowth #marketdata #marketsize #marketshare #markettrends #marketreport #marketoutlook #marketoverview #drivers #marketresearchreport #marketsegmentation #marketsummary #restraints #researchanddevelopment #researchmethods #researchreport #marketdemand

Exciting news! Collaborators from King's College Hospital London – UAE London, Murdoch University and Perron Institute for Neurological and Translational Science, Australia, have harnessed Pawsey's supercomputing power to unlock new insights into Amyotrophic Lateral Sclerosis (ALS). This groundbreaking research, led by Heather Marriott, Alfredo Iacoangeli, Abigail Pfaff, and Sulev Koks, sheds valuable light on the diverse characteristics of this fatal neurodegenerative disease and has the potential to pave the way for more accurate diagnoses, personalized treatment strategies, and targeted drug development. The Breakthrough: Researchers applied machine learning to motor cortex data from ALS patients, revealing three distinct molecular subtypes: 1. Synaptic signaling: Affects communication between neurons. 2. Oxidative stress and apoptosis: Involves cell damage. 3. Neuroinflammation: Focuses on chronic inflammation in the nervous system. Our supercomputing powerhouse processed and validated massive RNA sequencing data. Additionally, Setonix, Pawsey's flagship supercomputer, facilitated critical analysis, ultimately aiding in the identification of these crucial subtypes. The Impact: • Improved Diagnosis: Recognising patient differences could lead to more accurate and early diagnoses. • Personalised Treatment: Therapies can be tailored to specific subtypes, potentially enhancing effectiveness. • Targeted Drug Development: Research can focus on treatments addressing specific mechanisms within each subtype. Dive Deeper: To learn more about the study and its results, read the paper published by BMC, Part of Springer Nature bit.ly/3SOjGaC and access the code on GitHub bit.ly/3SLXQEJ. Looking ahead, this ground-breaking research paves the way for more research and has the potential to significantly improve the lives of ALS patients. Join the Conversation: #Pawsey #ALS #Research #Supercomputing #Breakthroughs #PersonalisedMedicine #Neuroscience #CollaborativeResearch #NCRISimpact ✨

Kariya is pleased to announce the successful dosing of the first cohort in a Phase 1 clinical trial of KP405, a novel, brain-penetrant, dual incretin (GLP-1/GIP) receptor agonist for the treatment of Parkinson’s Disease. The single center Phase I study is a first-in-human, randomized, placebo-controlled, clinical trial conducted by strategic partner MAC Clinical Research in Manchester, UK. The two-part study will evaluate the safety, tolerability, pharmacokinetics (PK), and potential pharmacodynamic (PD) effect of both single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneously administered KP405 in healthy subjects and Parkinson’s patients. #PhaseI #firstinhuman #clinicaldevelopment #endparkinsonsdisease #cureparkinsonsdisease #parkinsonsresearch #parkinsonsdisease #movementdisorders #patientsarewaiting #hope #BioInnovationInstitute #DKlifescience #DKBiotek #neuroscience #CNS #onestepcloser 

New findings regarding the latest #preclinical studies of #ALS are being presented at the #SfN meeting in #Chicago, pointing to #hope for #patients. #Researchers from Biogen describe optimization of intrathecal injection for improved delivery of ASO- or #AAV-based #therapeutics in a translational model (1).  A team from the laboratory of Gerardo Andres Morfini 🇦🇷 (University of Chicago) presents data showing a significant contribution of p38-alpha to mutant SOD1-induced axonal pathology and neuronal preservation, suggesting a potential #therapeutic target to treat ALS (2). Susanne Bäck and colleagues from #Finland report findings from analysis of walking in the SOD1 G93A model (3). Their #data validate previous findings by DigiGait (Mouse Specifics, Inc.) that stance width and foot placement angles narrow quite early (~6 weeks) when ALS mice are asked to walk fast up an incline (4).  DigiGait: See HOW They run! https://lnkd.in/eEsskBjR. I especially appreciated data presented from the #laboratory of Dr. Turgay Akay at Dalhousie University.  Reynaldo Popoli and colleagues showing that cholinergic antagonists improve behavioral performance, #muscle innervation, and #life expectancy in ALS mice (5).  Are some of the effects akin to those of ibudilast, a PDE-4 and PDE-10 inhibitor that suppresses pro-inflammatory molecules and promotes neurotrophic factors?  In use in #Japan for 3 decades for #stroke and #asthma, the hope is that ibudilast might benefit ALS patients.  Early #clinical data suggest that ibudilast may delay ALS progression and increase #survival.  The The National Institutes of Health recently awarded a$22M grant to the Mayo Clinic for a #clinicaltrial to allow 200 patients to receive the drug (MN-166), provided by MediciNova, Inc. #health #wellness #innovation #neuroscience #animalwelfare #covid19 #pharmaceuticals #research References: 1.       Jussi Toivanen et al. Early synaptic and gait changes in the SOD1 G93A ... Program No. PSTR108.06. 2024 Neuroscience Meeting Planner. Chicago, IL. : Society for Neuroscience, 2024. Online. 2.       Twinkle Chowdhury et al. Optimization of intrathecal injection procedure for improved delivery of #ASO- or AAV-based .... Program No. PSTR429.07. 2024 Neuroscience Meeting Planner. Chicago, IL. : Society for Neuroscience, 2024. Online. 3.       Lorena Noriega Aguirre et al. Addressing contributions of aberrant p38alpha MAPK signaling to axonal degeneration ... Program No. PSTR108.05. 2024 Neuroscience Meeting Planner. Chicago, IL. : Society for Neuroscience, 2024. Online. 4.       Vinsant S, et al. et Carol Milligan. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results & discussion. Brain Behav. 2013 Jul;3(4):431-57. 5.       R.Popoli, Tyler Wells, et al. Cholinergic antagonists improve behavioural performance, muscle ... Program No. PSTR108.09. 2024 Neuroscience Meeting Planner. Chicago, IL. : Society for Neuroscience, 2024. Online.

Toxic RNAs linked to Alzheimer's brain cell death Researchers from Northwestern University and other institutions have discovered a link between short toxic RNA strands and brain cell death in Alzheimer's disease and aging brains. The study identified that toxic short RNA strands contribute to neuron death, with their activity typically countered by protective RNAs like microRNAs. However, the numbers of protective RNAs decrease with aging, allowing toxic RNA strands to take over. The findings suggest that increasing the number of protective RNAs could be a novel approach to halt or delay Alzheimer's and neurodegeneration. Read more: https://lnkd.in/dPpnFQs7 #rna #alzheimer #research #medical #biology